Christopher Tormey, MD
Professor of Laboratory MedicineCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Transfusion Medicine Service, Laboratory Medicine
Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Transfusion Medicine Service, Laboratory Medicine
Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Transfusion Medicine Service, Laboratory Medicine
Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
About
Titles
Professor of Laboratory Medicine
Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory Medicine
Biography
Christopher A. Tormey, MD is a pathologist (board certified in Clinical Pathology as well as Blood Banking/Transfusion Medicine) in the Department of Laboratory Medicine at Yale University. Clinically, Chris is the Medical Director of Transfusion & Apheresis Services at Yale-New Haven Hospital (New Haven, CT), also providing Clinical Pathology and Laboratory Hematology/Coagulation services at Yale-New Haven Hospital. From the research standpoint, Chris has several investigative interests including: alloimmunization to non-ABO antigens in the setting of transfusion or pregnancy; examining the platelet storage lesion; and optimizing test performance/interpretation in hemostasis assays. In addition to the above, Chris is also the Director of the Transfusion Medicine fellowship at Yale and teaches medical/PA/nursing students, residents, and fellows at the Yale School of Medicine.
Appointments
Laboratory Medicine
ProfessorPrimary
Other Departments & Organizations
- Apheresis
- Apheresis/Transfusion Service
- Blood Bank
- Laboratory Medicine
- Laboratory Medicine - Education
- VA Connecticut Clinical Laboratories
- Yale Medicine
- Yale Ventures
Education & Training
- Clinical Fellow (Transfusion Medicine)
- Yale University School of Medicine (2008)
- Resident
- Yale University School of Medicine (2007)
- MD
- New York Medical College (2004)
- BA
- University of Chicago, Chemistry (2000)
Research
Overview
Medical Research Interests
ORCID
0000-0003-1785-2245
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Alexa Siddon, MD
Jeanne Hendrickson, MD
Richard Torres, MD, MS, BS
Henry Rinder, MD
Raisa Balbuena-Merle, MD, MHS
Alfred Lee, MD, PhD
Blood Group Antigens
Blood Group Incompatibility
Platelet Function Tests
Blood Coagulation Tests
Blood Platelet Disorders
Publications
2024
Optimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024 DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchConceptsNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testAssessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis
Musante K, Roome L, Yurtsever N, Rinder H, Tormey C, Lee E. Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis. American Journal Of Clinical Pathology 2024, 162: s147-s147. DOI: 10.1093/ajcp/aqae129.326.Peer-Reviewed Original ResearchConceptsSickle cell diseaseRed blood cell unitsSickle cell disease patientsRed blood cellsPatient's HctRBC unitsTransfused RBC unitsRetrospective chart reviewTwo-sample t-testChart reviewAdverse eventsMedian numberPre-procedureProphylactic procedureCell diseasePatientsAcademic hospitalAverage hematocritAverage HctBlood cellsHctTransfusion servicesT-testQuality studiesHematocritCurrent state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024, 99: 2351-2366. PMID: 39324647, PMCID: PMC11560617, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchAltmetricConceptsHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRnThe effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, lmae080. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforCharacterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States
Jacobs J, Booth G, Moise K, Adkins B, Bakhtary S, Fasano R, Goel R, Hinton H, Laghari S, Stephens L, Tormey C, Crowe E, Bloch E, Abels E. Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States. Transfusion 2024, 64: 1870-1880. PMID: 39248602, DOI: 10.1111/trf.18011.Peer-Reviewed Original ResearchAltmetricConceptsRisk of HDFNAntigen testAntibody titersHemolytic diseaseRed blood cellsCell-free fetal DNA testingRisk of hemolytic diseaseCell-free fetal DNAMaternal antibody titersPregnant individualsFetal DNA testingBlood banksTransfusion medicine practiceFetal DNALaboratory testing practicesThird trimesterAntigen statusTransfusion medicine serviceAntigen resultsMedicine serviceFetusesHDFNCritical titerResponse rateDNA testingMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftmentThe seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs J, Stanek C, Booth G, Symeonidis A, Shih A, Allen E, Gavriilaki E, Grossman B, Pavenski K, Moorehead A, Peyvandi F, Agosti P, Mancini I, Stephens L, Raval J, Mingot‐Castellano M, Crowe E, Daou L, Pai M, Arnold D, Marques M, Henrie R, Smith T, Sreenivasan G, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Harrington T, Byrnes D, Bitsani A, Davis A, Robinson D, Eichbaum Q, Villalba C, Juskewitch J, Kaiafa G, Kapsali E, Klapper E, Perez‐Alvarez I, Klein M, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhateb R, Fortuny L, Mellios Z, Papalexandri A, Parsons M, Schlueter A, Tormey C, Wellard C, Wood E, Jia S, Wheeler A, Powers A, Webb C, Yates S, Bouzid R, Coppo P, Bloch E, Adkins B. The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes. American Journal Of Hematology 2024, 99: 2063-2074. PMID: 39136282, DOI: 10.1002/ajh.27458.Peer-Reviewed Original ResearchAltmetricAddressing platelet insecurity – A national call to action
Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, DOI: 10.1111/trf.17987.Peer-Reviewed Original ResearchEfgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original ResearchCitationsAltmetricTherapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, lmae054. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
honor President's Award
National AwardAABBDetails10/14/2023United Stateshonor ASCP Mastership (MASCP)
National AwardAmerican Society for Clinical PathologyDetails10/29/2021United Stateshonor Resident Teaching Award
Yale School of Medicine AwardDept. of Laboratory MedicineDetails06/30/2019United Stateshonor The Ellis Benson Award
National AwardAcademy of Clinical Laboratory Physicians and ScientistsDetails06/13/2015United Stateshonor 40 Under 40 Awardee
National AwardAmerican Society for Clinical PathologyDetails10/10/2014United States
Clinical Care
Overview
Christopher Tormey, MD, is a pathologist who specializes in diagnosing blood, or hematological, disorders. Some of the conditions he might diagnose include bleeding or clotting disorders, anemia, sickle cell disease, and also blood cancers, including leukemia and lymphoma. Dr. Tormey is medical director of the transfusion service at the VA Connecticut Healthcare System in West Haven.
“I help make a diagnosis through lab tests and looking at samples under a microscope,” Dr. Tormey says. “Then I work with the patient to find the best solution for them.” He explains that this could be an apheresis treatment, in which a patient’s blood is filtered and replenished with a healthy supply, or it could involve a blood plasma transfusion. “It’s rewarding to provide a definitive answer and make a meaningful contribution to a patient’s therapy,” Dr. Tormey says.
At Yale School of Medicine, Dr. Tormey is an associate professor of laboratory medicine. In his research, he investigates the immune system and the presence of certain antibodies in the blood.
Clinical Specialties
Board Certifications
Clinical Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2019
- Original Certification Date
- 2008
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- September 10, 2024
Spleen Removal as Treatment for Primary Warm Autoimmune Hemolytic Anemia
- April 09, 2024
Laboratory Medicine Faculty honored as AABB 2023 President's Award Recipients
- August 11, 2022
Discoveries & Impact (August 2022)
- August 11, 2021
Discoveries & Impact (August 2021)
Get In Touch
Contacts
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Locations
Dept. of Laboratory Medicine
Academic Office
55 Park Street, Fl 3, Rm 329D
New Haven, CT 06511
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.